Mountain range with trees and river
Info Sheet , Sustainability

Quotient Sciences 2023 ESG Report

10 December 2024
Overview

Our ESG commitments are closely aligned with our mission to accelerate the development of new medicines for patients. 

We hold ourselves accountable, knowing that ethical practices build trust and resilience. At the start of 2024, the company set five ambitious sustainability goals as part of its corporate strategy, including launching a new diversity, equity, and inclusion training program and engaging with suppliers in order to better understand their own ESG initiatives and targets for improvement. 

As highlighted in our inaugural ESG report, compiled with data from 2023, Quotient Sciences and its colleagues have made progress on each of these initiatives over the past year. 

Find our more about our commitments

Download The Report
Date
10 December 2024
Two hands holding a small Earth ball
Sustainability

Exploring Energy Efficiency & Sustainability in the Pharmaceutical Outsourcing Industry

Read More

Latest news

News & Announcements, Articles & Publications, commercial manufacturing, Dr. Helen Baker, Dr. Richard Castledine Dr. Helen Baker and Dr. Richard Castledine contribute to Pharmaceutical Technology's 'Poor API Quality Threatens a Healthy Supply' By: Dr. Helen Baker and Dr. Richard Castledine
Learn more
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Learn more
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Learn more
Get in touch
Humanity can't afford to wait, so neither can we.